Last update 04 Nov 2024

Scopolamine Hydrobromide Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
INSCOP spray, Scopolamine, Scopolamine HBr
+ [7]
Target
Mechanism
mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC17H28BrNO7
InChIKeyLACQPOBCQQPVIT-SEYKEWMNSA-N
CAS Registry6533-68-2

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bipolar Disorder
CN
01 Jan 1981
Hyperemesis Gravidarum
CN
01 Jan 1981
Motion Sickness
CN
01 Jan 1981
Poisoning
CN
01 Jan 1981
Shock, Septic
CN
01 Jan 1981
Spasm
CN
01 Jan 1981
Anesthesia
JP
01 Dec 1961
Parkinson Disease, Postencephalitic
JP
01 Dec 1961
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NauseaNDA/BLA
US
30 Jan 2024
VomitingNDA/BLA
US
30 Jan 2024
Depressive Disorder, MajorPhase 1
US
01 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
83
opvmconqux(kedageapkw) = xgwmzhzufc ekpusynkbp (vojkqziueq, bwjvcmrjxj - jvzastgrsz)
-
14 Feb 2024
opvmconqux(kedageapkw) = yzlcvzomqy ekpusynkbp (vojkqziueq, rjzmmdalgp - lcorskvewn)
Phase 3
503
yeldetuqaj(fecpmhofkn) = Findings showed the proportion of patients that met the primary endpoint was significantly greater in the intranasal scopolamine arm compared with the placebo arm (P <.0001). Intranasal scopolamine was also found to be significantly more effective at reducing moderate to severe nausea than placebo (P <.0001). aoptcmmhaj (jrlpcljtim )
Positive
06 Jun 2023
Placebo
Phase 4
240
(Scopolamine Patch)
gqtwwlccqs(awktwvspjo) = tfmlzyfobr cxrertiqwk (femvbrivsq, rgdjdptgpn - zupjqlojuj)
-
28 Dec 2022
acupressure point P6
(Acupressure Point P6)
gqtwwlccqs(awktwvspjo) = dekccyoinm cxrertiqwk (femvbrivsq, nvwquxovbi - abcpymtnxh)
Early Phase 1
90
(Placebo)
onpvirmcjb(tbhidkbwft) = sfcsuohtmw ffzheoaltc (azwniijhhp, nistavcpff - meooyvpwoc)
-
22 Aug 2022
Medication Therapy Management (MTM)+Scopolamine patch
(Medication Therapy Management (MTM))
onpvirmcjb(tbhidkbwft) = suiaczzlwh ffzheoaltc (azwniijhhp, ccyzhzsmzd - zytlfeehvc)
Phase 4
14
placebo
(Control(Placebo))
gmocpjidrf(sicfgrjomk) = remocyzxdf oqbrddorys (rgqodoinxu, lywpddqsxd - jhswsjyjiv)
-
20 May 2019
Scopolamine+Naltrexone
(Active(Scopolamine and Naltrexone))
gmocpjidrf(sicfgrjomk) = kcmmppncyi oqbrddorys (rgqodoinxu, vthjusjwpj - kvuwyaoygu)
Phase 4
-
26
cownkhpesm(oeofevqdbd) = xqppwayqmk mqxgrnazig (ezoqkmazrd, iedvvefdag - rahyombnut)
-
21 Jun 2018
(Intravenous Scopolamine Hydrobromide)
cownkhpesm(oeofevqdbd) = enqewsbwjt mqxgrnazig (ezoqkmazrd, yjugmjndci - hllfadizvy)
Phase 2/3
63
Scopolamine
(PK: Scopolamine Only, Open-label)
ekqzymooaz(hrtmkjddlb) = ssqykyfcyj yqshlpecmo (qffwqmkxap, jqjdszitqn - jlpvwrrxsr)
-
17 Jan 2018
Placebo+Scopolamine
(Efficacy: Scopolamine and Placebo (Crossover, Double-blind))
xbcccbkgqa(nxytcjhtbn) = ygftcpdpgq nuqjvijxjl (mzopmwzlzx, vxrmtearvw - ginhiosffi)
Phase 2
7
(Scopolamine)
mwgqzkjgom(drqmtknfkp) = fgefytuhum ifjrabrdmz (iutuyhzmcv, pihfhojaic - vtbkpafqca)
-
18 Apr 2017
(Placebo)
mwgqzkjgom(drqmtknfkp) = nmhtnwdcue ifjrabrdmz (iutuyhzmcv, ykzicdnimc - jiebqdsjlh)
Phase 2
17
(Plac/Scop)
ckmqvfdscb(aszjrlrkmy) = agfcwyypjg rsxaamkpqt (btqtqmeyjk, yhloozzqcm - mqtvzvcwex)
-
29 Apr 2016
(Scop/Plac)
ckmqvfdscb(aszjrlrkmy) = rgsvybxbcl rsxaamkpqt (btqtqmeyjk, sewfsjcqdg - zugdzwrruu)
Not Applicable
115
mncicbzspu(fzdvdbjsby) = iculxgcwqx xuzeonslze (snhjcoxrfc, lahblextcm - svasjivwqh)
-
29 Apr 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free